Emplimet XR 10mg/5mg/1000mg Tablets (30s)

Description

Emplimet XR is a once-daily extended-release combination tablet containing empagliflozin, linagliptin, and metformin for adults with type 2 diabetes mellitus. It helps improve blood glucose control through complementary glucose-lowering mechanisms.

• Manufacturer Name: Horizon
• Drug Class: Antidiabetic combination: SGLT2 inhibitor, DPP-4 inhibitor, and biguanide
• Dosage Form: Extended-Release Tablet
• Storage: Store at room temperature below 30°C in the original packaging. Protect from moisture, heat, and direct light. Keep out of reach of children.
• Pack Size: Pack of 30 Tablets

Emplimet XR 10mg/5mg/1000mg Tablets (30s) Available Online in Pakistan

Dwatson offers Emplimet XR 10mg/5mg/1000mg Tablets (30s) at Rs. 750, with fast, discreet delivery across Pakistan.

Ingredients

• Empagliflozin 10 mg
• Linagliptin 5 mg
• Metformin hydrochloride extended-release 1000 mg

Benefits

• Improves blood glucose control in adults with type 2 diabetes mellitus when diet and exercise alone are insufficient.
• May be used when treatment with the individual components is appropriate.
• Empagliflozin may provide additional cardiovascular and kidney-related benefits in selected patients, as determined by a healthcare professional.

Usage & Safety

For Adult

• Take one tablet once daily with a meal, preferably in the morning, or as directed by the prescriber.
• Swallow whole with water; do not crush, split, or chew the extended-release tablet.
• Dosage should be individualized according to blood glucose control, kidney function, tolerability, and previous therapy.
• Maintain adequate fluid intake unless fluid restriction has been prescribed.

For Children

• Safety and effectiveness in children and adolescents under 18 years have not been established for this fixed-dose combination.
• Not recommended for routine pediatric use unless specifically prescribed by a specialist.
• No pediatric weight-based dosing recommendation is established for this product.

Side Effects

• Common effects may include nausea, diarrhea, abdominal discomfort, reduced appetite, increased urination, and mild dehydration.
• Genital fungal infections and urinary tract infections may occur, particularly with empagliflozin.
• Low blood sugar is more likely when used with insulin or sulfonylureas.
• Seek urgent medical care for symptoms of ketoacidosis, severe weakness, vomiting, abdominal pain, rapid breathing, confusion, or unusual drowsiness.
• Seek immediate care for severe allergic reactions, facial or throat swelling, difficulty breathing, severe persistent abdominal pain, or signs of lactic acidosis.
• Rare but serious risks include severe dehydration, kidney injury, serious genital or urinary infections, pancreatitis, and lactic acidosis.

Contraindications

• Do not use in patients with a known allergy to empagliflozin, linagliptin, metformin, or any component of the tablet.
• Contraindicated in severe kidney impairment, dialysis, or conditions with substantially reduced kidney function.
• Do not use in metabolic acidosis, including diabetic ketoacidosis, or lactic acidosis.
• Use is not appropriate for treatment of type 1 diabetes.
• Use caution or avoid during severe dehydration, serious infection, shock, acute heart failure exacerbation, or conditions causing tissue oxygen shortage.
• Temporarily discontinue around iodinated contrast imaging when clinically indicated and restart only after kidney function has been reassessed.

Precautions & Warnings

• Insulin and sulfonylureas may increase the risk of hypoglycemia; dose adjustment may be required.
• Diuretics and other medicines that lower blood pressure may increase dehydration or low blood pressure.
• Iodinated contrast agents may increase the risk of kidney injury and metformin-associated lactic acidosis.
• Excessive alcohol intake increases the risk of lactic acidosis and should be avoided.
• Medicines that affect kidney function or metformin elimination require medical review.
• Strong enzyme inducers, such as rifampicin, may reduce linagliptin effectiveness.
• Tell the healthcare professional about all prescription medicines, over-the-counter products, and herbal supplements before use.

Pregnancy

• Use during pregnancy is not generally recommended unless clearly prescribed after an individual medical assessment.
• Empagliflozin is generally avoided during the second and third trimesters because of potential effects on the developing fetal kidneys.
• Inform the prescriber immediately if pregnancy occurs or is planned.
• Breastfeeding is generally not recommended during treatment because empagliflozin and metformin may pass into breast milk and the effects on the infant are not fully established.